Teva Pharmaceutical Industries Limited (TEVA) Discusses Positive Topline Results for Anti-IL-15 Antibody in Phase IIa Celiac Disease Study TranscriptSeeking Alpha • 09/02/26
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product PotentialGlobeNewsWire • 09/02/26
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized DrugmakersZacks Investment Research • 09/01/26
Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.GlobeNewsWire • 08/31/26
Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset BidZacks Investment Research • 08/31/26
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth StrategyGlobeNewsWire • 08/28/26
TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette SyndromeZacks Investment Research • 08/20/26
U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette SyndromeGlobeNewsWire • 08/19/26
Teva Q2 Earnings Lag Estimates, 2026 Revenue View Raised, Stock RisesZacks Investment Research • 07/30/26